The trial enrolled 703 participants who had previously received one or more lines of systemic therapy.

Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 3 SigVie-002 study (previously known as Be6A Lung-01) ...

The drug, acquired in Pfizer's $43 billion purchase of Seagen, did not outlast standard chemotherapy in a 703-patient study ...

The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are ...

Pfizer's lung cancer drug trial update, oncology pipeline strategy, Seagen deal impact, and subgroup opportunity in non small ...

Patients who had received only one prior line of systemic therapy showed a stronger trend for overall survival and ...

Things are going from bad to worse for the pharmaceutical giant.

A post-marketing trial finds the oral antiviral achieves effective blood concentrations in at-risk children aged 6 years or older with mild-to-moderate COVID.

Pfizer's lung cancer drug trial fails to show significant improvement in overall survival: New York Wednesday, June 24, 2026, 09:00 Hrs [IST] Pfizer Inc., announced topline result ...

One of the antibody-drug conjugates at the heart of Pfizer's $43 billion acquisition of Seagen three years ago has failed a ...

Pfizer Inc. said an experimental drug failed to improve survival in patients with an advanced form of lung cancer that couldn ...

Pfizer's experimental drug sigvotatug vedotin failed to improve survival in advanced non-small cell lung cancer patients compared to standard therapy, Pfizer announced.